European Journal of Cancer
Volume 41, Issue 18 , Pages 2836-2845 , December 2005

Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy

  • Gaetano Bacci

      Affiliations

    • Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 051 6366 829/199; fax: +39 051 6366 277.
    • ,
  • Alessandra Longhi

      Affiliations

    • Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    • ,
  • Franca Fagioli

      Affiliations

    • Section of Pediatric Oncology, OIRM S.Anna, Torino, Italy
    • ,
  • Antonio Briccoli

      Affiliations

    • Section of Thoracic Surgery, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    • ,
  • Michela Versari

      Affiliations

    • Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    • ,
  • Piero Picci

      Affiliations

    • Section of Oncologic Research, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

Received 17 May 2005 ,Revised 10 August 2005 ,Accepted 10 August 2005.

References 

  1. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Ortopedico Rizzoli experience in 127 patients treated pre-operatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65:2539–2553
  2. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002;9:171–175
  3. Ferrari S, Mercuri M, Picci P, et al. Non-metastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumour response. Tumouri. 1999;85:458–464
  4. Bacci G, Ferrari S, Longhi A, et al. High-dose ifosfamide in combination with high-dose methotrexate, doxorubicin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198–206
  5. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 2001;37:2030–2039
  6. Enneking WF, Spanier S, Goodman MA. A system for the surgical staging of musculoskeletal sarcomas. Clin Orthop. 1980;153:106–120
  7. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer. 1985;56:1515–1521
  8. Rosen G, Caparros B, Huvos AG, et al. Pre-operative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant chemotherapy based on response of the primary tumour to pre-operative chemotherapy. Cancer. 1982;49:1221–1230
  9. Longhi A, Pignotti E, Versari M, et al. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep. 2003;10:151–155
  10. Longhi A, Macchiagodena M, Vitali G, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol. 2003;25:292–296
  11. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423–431
  12. Bieling P, Rehan N, Winkler P, et al. Tumour size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–858
  13. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for non-metastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580
  14. Delepine N, Delepine G, Desbois JC. Monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocol based upon HDMTX, associated with systematic conservative surgery. In:  Humphrey GB editors. Osteosarcoma in adolescent and young adults. Boston: Kluver Academic Publisher; 1993;
  15. Kalifa C, Razafindrakoto H, Vassal G, et al. Chemotherapy in osteogenic sarcoma: the experience of the pediatric department of the Gustave Roussy Institute. Cancer Treat Res. 1993;62:347–349
  16. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the memorial Sloan Kettering experience. J Clin Oncol. 1992;10:5–15
  17. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol. 1984;12:617–624
  18. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumour response. J Clin Oncol. 1988;29:331–337
  19. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;21:890–899
  20. Goorin AM, Perez-Atayde A, Gebhardt M, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma; the Dana Farber Cancer Institute/the Children’s Hospital-study III. J Clin Oncol. 1987;5:1178–1184
  21. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastatic osteosarcoma of the extremity with pre-operative and post-operative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76–84
  22. Bacci G, Ferrari S, Mercuri M, et al. predictive factors for local recurrence in osteosarcoma. Acta Orthop Scand. 1998;69:230–236
  23. Smeland S, Muller C, Alvegard T, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488–494

PII: S0959-8049(05)00798-7

doi: 10.1016/j.ejca.2005.08.026

European Journal of Cancer
Volume 41, Issue 18 , Pages 2836-2845 , December 2005

Article Tools